Related Experiment Video
Updated: Jan 18, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.4K
Treatment Persistence After Major Cardiovascular Events in Psoriasis: A Retrospective Cohort Study Comparing
Hyun Keun Ahn1, Sohee Oh2, Hyun-Sun Yoon3,4
1Department of Dermatology, Seoul National University Hospital, Seoul, Korea.
The Journal of Dermatology
|September 8, 2025
Summary
Patients with psoriasis on biologic therapies show higher treatment persistence after cardiovascular events compared to other treatments. This suggests biologics are viewed as safer for high-risk psoriasis patients post-cardiac events.
Area of Science:
- Dermatology and Cardiology
- Pharmacovigilance
- Health Services Research
Background:
- Psoriasis patients have increased cardiovascular risk.
- Lack of guidelines for psoriasis treatment continuation after major adverse cardiovascular events (MACE).
Purpose of the Study:
- To examine psoriasis treatment modifications after MACE.
- To compare treatment persistence across different psoriasis therapies post-MACE.
Main Methods:
- Retrospective cohort study using Korean health insurance data (2008-2021).
- Categorized patients by treatment: biologics, non-biologic systemics (cyclosporine, methotrexate), and phototherapy.
- Assessed treatment persistence within 3 months post-MACE using multivariable logistic regression.
Main Results:
- Biologics showed significantly higher treatment persistence (79.7%) versus non-biologics (46.9%) and phototherapy (47.0%).
- Biologics were strongly associated with greater persistence compared to cyclosporine, methotrexate, and phototherapy.
- Treatment switching was infrequent across all groups (0.8%-1.9%).
Conclusions:
- Biologic therapies are more likely continued post-cardiovascular event in psoriasis patients.
- Findings suggest biologics are perceived as safer in this high-risk population.
- Highlights the need for evidence-based guidelines on psoriasis treatment post-cardiac events.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
506
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
506
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
466
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
466
01:21Rheumatic Heart Disease III: Medical Management
290
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
290
01:26Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
571
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
571
01:14Changes in Skin Color: Clinical Perspectives
3.3K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
3.3K